Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (1706)	1/29/2015 11:08:45 PM
From: Felix B	Respond to of 3559

Really curious on this readout as well as Eylea + PDGFR mAb or Eylead + Ang2 mAb, any idea when those are reading out?

To: DewDiligence_on_SI who wrote (1706)	1/30/2015 12:26:51 AM
From: Miljenko Zuanic	Respond to of 3559

Thanks, saw that. NVS seams confident, and it may be small incremental improvement (single chain small antibody), but next significant improvement in AMD (and DME) space would be VEGF-PDGF combo in single IV-i (or single vector gen therapy). RE: Precision medicine Friday meeting, Y spelled it correctly at JPM...separate and identify small signal in huge gen-info noise! Much easy to say than do! REGN is already deep into it at their Genomic Center.